Physician profile
Thomas J Bullock
NPI 1578907671
$8,411.38
in general payments reported to CMS, 2019-2025
25 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 76% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2023: $245 · 2024: $6,129 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,470 · Food and Beverage: $2,349 · Travel and Lodging: $1,364 · Education: $67.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,470.00 |
| Food and Beverage | $2,348.71 |
| Travel and Lodging | $1,364.21 |
| Education | $67.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $6,370.00 | 2023-2025 | Rystiggo, Fintepla, Briviact |
| Sk Life Science, INC. | $539.09 | 2024-2025 | Xcopri |
| Livanova USA, INC. | $254.49 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $137.73 | 2024-2025 | |
| Lilly USA, LLC | $126.97 | 2023-2025 | Amyvid, Kisunla |
| Merz Pharmaceuticals, LLC | $91.36 | 2025 | Xeomin, Inbrija |
| Abbott Laboratories | $86.33 | 2025 | Infinity |
| Neurelis, INC. | $83.13 | 2023-2025 | Valtoco |
| Neuropace, INC. | $72.33 | 2024 | |
| Tg Therapeutics, INC. | $63.78 | 2025 | |
| Argenx US, INC. | $62.65 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $60.69 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $54.94 | 2024 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $52.68 | 2024-2025 | Onpattro, Amvuttra |
| Lundbeck LLC | $49.82 | 2024-2025 | Vyepti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $46.99 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $41.51 | 2024-2025 | |
| Boston Scientific Corporation | $40.00 | 2023-2025 | Vercise |
| Janssen Biotech, INC. | $30.58 | 2025 | |
| Emd Serono, INC. | $28.29 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $27.79 | 2024 | Dysport |
| Pfizer INC. | $26.19 | 2024 | |
| Tanabe Pharma America, INC. | $23.77 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $22.83 | 2025 | Austedo Xr |
| Amgen INC. | $17.44 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bullock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.